Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hemoglobinuria, Paroxysmal 4Carcinoma, Hepatocellular 3Squamous Cell Carcinoma of Head and Neck 2Neuroblastoma 2Neoplasms 2Melanoma 2Liver Diseases 2Leukemia 2Hodgkin Disease 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Prostatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Histiocytosis 1Hemoglobinuria 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Antibodies × Clear all
NCT05259397 2023-03-08

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Pfizer

Phase 1 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡